8-K: XOMA Corp Completes Acquisition of Kinnate Biopharma in Merger Deal

XOMA Corporation has finalized its acquisition of Kinnate Biopharma, completing a tender offer and subsequent merger on April 3, 2024.

Summary

• XOMA Corporation completed its acquisition of Kinnate Biopharma on April 3, 2024, through a merger.
• The acquisition involved a tender offer where XOMA purchased Kinnate's outstanding shares for $2.5879 in cash per share, plus a contingent value right (CVR).
• Approximately 81% of Kinnate's outstanding shares were tendered, satisfying the minimum tender condition.
• Following the tender offer, a merger was completed, with Kinnate becoming a wholly-owned subsidiary of XOMA.
• Holders of Kinnate stock options and restricted stock units received cash and/or CVRs based on the terms of the merger agreement.
• The CVRs represent the right to receive potential payments based on future events related to the acquired assets.
• The CVR agreement outlines the terms for potential payments to holders based on the disposition of certain assets within a specified period.

Sentiment

Score: 7

Explanation: The document indicates a successful completion of a strategic acquisition, which is generally positive. However, the reliance on CVRs introduces uncertainty, which tempers the overall sentiment.

Positives

• The acquisition was successfully completed, meeting all conditions.
• Shareholders of Kinnate received immediate cash consideration.
• The CVRs offer potential for additional future payments based on the performance of the acquired assets.
• The merger was completed without the need for a stockholder vote.

Negatives

• The CVRs are contingent and may not result in any future payments.
• Out-of-the-money option holders only received CVRs, with no immediate cash payment.
• The CVRs are non-transferable, limiting the ability of holders to realize value before any potential payout.

Risks

• The value of the CVRs is dependent on the future disposition of certain assets, which is not guaranteed.
• There is a risk that no disposition will occur during the specified period, resulting in no payments to CVR holders.
• The CVR agreement includes complex terms and conditions that could impact the amount and timing of potential payments.
• The CVRs are non-transferable, limiting the ability of holders to realize value before any potential payout.

Future Outlook

The future value for CVR holders is dependent on the successful disposition of certain assets within a specified period, with potential payments based on the proceeds from such dispositions.

Management Comments

• XOMA issued a press release announcing the completion of the Merger on April 3, 2024.

Industry Context

This acquisition represents a strategic move by XOMA to expand its portfolio and pipeline through the acquisition of Kinnate's assets and technologies. This is a common strategy in the biopharmaceutical industry to acquire promising drug candidates and technologies.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) is a relatively common mechanism in biotech and pharmaceutical acquisitions, particularly when the value of the acquired company's assets is uncertain or dependent on future milestones.
• Similar deals often include upfront cash payments and CVRs tied to regulatory approvals, sales milestones, or other performance metrics.
• The 81% tender rate is a strong indication of shareholder support for the deal, which is typical in successful acquisitions.
• The structure of the deal, with cash and CVRs, is similar to other acquisitions in the biotech space, such as the acquisition of Immunomedics by Gilead, which also included a CVR component.

Stakeholder Impact

• Kinnate shareholders received cash and potential future payments through CVRs.
• XOMA shareholders may benefit from the acquisition of Kinnate's assets and technologies.
• Employees of Kinnate will become part of XOMA.

Next Steps

• XOMA will integrate Kinnate's assets and operations.
• XOMA will manage the disposition of certain assets to potentially trigger CVR payments.
• The Rights Agent will manage the CVR register and payments to holders.

Key Dates

Keywords

acquisition, merger, contingent value rights, tender offer, biopharma, XOMA, Kinnate, CVR, pharmaceuticals, stock options, restricted stock units